OpGen has launched an expanded molecular testing and bioinformatics program for detecting and managing gram-negative multi-drug resistant organisms (MDRO). The products and services that the company is offering through its program are designed to help healthcare providers identify and treat infected patients.
Specifically, the company is offering its Acuitas suite of MDRO tests and its Acuitas Lighthouse MDRO management system. The company's Acuitas Resistome test detects approximately 50 antibiotic resistance genes in gram-negative bacteria, while its Acuitas whole-genome sequence analysis service provides high-resolution strain typing and subtyping for a full spectrum of resistance genes. The company has also released an early iteration of its Acuitas Lighthouse MDRO management system, which provides molecular information about patients' resistance profiles and integrates that data with other patient and hospital-wide data to help improve overall patient outcomes and reduce hospital costs. OpGen expects to launch a full web-based version of the Lighthouse management system in the third quarter of 2015.
These new products and services are available from OpGen's CLIA testing laboratory.